Aethlon Medical Releases Biodefense Report.

Business Editors/Health/Medical Writers

LA JOLLA, Calif.--(BUSINESS WIRE)--Oct. 20, 2003

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that a report entitled: "Business Opportunities in Biodefense" is now available and can be accessed from the Industry Reports button at the Company's website: www.AethlonMedical.com. The report, published by U.S. InterMed, LLC, represents an in-depth analysis of the Biodefense Industry and discusses opportunities for Aethlon Medical to expand the utilization of its Hemopurifier(TM) platform technology as a treatment against biowarfare agents.

The report details how the Hemopurifier may fill a void in the armamentarium of available treatments for several organisms that may be released either as 'natural epidemics' or deliberately as weapons of bioterror. Specifically, as a treatment against organisms that circulate in the blood prior to organ infection and are of a molecule size that is able to diffuse and be captured within the membrane of Aethlon's Hemopurifier. Anthrax, Ebola, and Smallpox are among the candidate targets. A listing of other bio-weapons potentially treatable by the Hemopurifier is charted on page fifteen of the report.

About Aethlon Medical

Aethlon Medical is developing therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45 removed 55% of HIV from human blood in three hours and in excess of 85% in twelve hours. AEMD-45 is also able to clear 90% of toxic proteins (gp-120) that deplete immune cells in one hour.

AEMD-45, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method to increase the capability of FDA cleared artificial kidneys (hemodialysis cartridges) to bind infectious viruses and toxic proteins from human blood before cells are infected. In January of 2003, the Company completed early stage blood studies of its HCV-Hemopurifier, which documented the ability to remove 58 percent of the Hepatitis-C virus from infected blood in two hours. For more information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.